Clinical Trials Logo

Acidosis, Lactic clinical trials

View clinical trials related to Acidosis, Lactic.

Filter by:

NCT ID: NCT04766008 Recruiting - Clinical trials for Coronary Artery Disease

Metformin in Diabetic Patients Undergoing Coronary Angiography

NO-STOP
Start date: January 15, 2020
Phase: Phase 4
Study type: Interventional

The present study aims to evaluate the strict application of the 2018 European Society of Cardiology guidelines on myocardial revascularization, that recommends to check renal function if patients have taken metformin immediately before angiography and withhold metformin if renal function deteriorates. The aim of this study is to assess the safety of metformin in diabetic patients undergoing coronary angiography in terms of risk of lactic acidosis and to individuate eventual predictors of augmented lactic acid after coronary angiography.

NCT ID: NCT04762966 Recruiting - Clinical trials for Metformin Associated Lactic Acidosis

Study of Metformin Overdose

METINFO
Start date: March 1, 2021
Phase:
Study type: Observational

The objective of the METINFO study is an observational single-center retrospective and descriptive study. The main objective is to estimate the real mortality rate associated to a Metformin overdose. Second objectives are to estimate the real hospitalization rate related to metformin overdose and to identify the risk factors of a metformin overdose and especially the potential correlation between metformin blood concentration and overdose severity.

NCT ID: NCT04604548 Not yet recruiting - Clinical trials for Mitochondrial Diseases

The KHENEREXT Study

Start date: April 2021
Phase: Phase 2
Study type: Interventional

This is an open-label, multi-centre study in subjects with a genetically confirmed mitochondrial deoxyribonucleic acid (DNA) transfer ribonucleic acid (tRNA)Leu(UUR) m.3243A>G mutation who completed study KH176-202. In the KH176-203 study subjects will be receiving KH176 100 mg BID or KH176 50 mg bid in die (BID) (as determined by the investigator based on safety / tolerability considerations) for a year, thereby ensuring continued treatment with KH176 after study KH176-202. A final follow-up visit is scheduled 4 weeks after the intake of the last dose of study medication for patients not rolling over into the compassionate use program.

NCT ID: NCT03723993 Withdrawn - Lactic Acidosis Clinical Trials

Remote Ischemic Preconditioning During Cardiopulmonary Bypass

RIPC
Start date: January 15, 2018
Phase: N/A
Study type: Interventional

The objective of study is to detect effect of remote ischemic preconditioning on serum lactate levels during and after cardiac surgery with cardiopulmonary bypass in addition to its effect on cardiac and renal clinical outcomes.

NCT ID: NCT03522181 Completed - Clinical trials for Liver Transplantation

Glucose-insulin-potassium Therapy Improves Lactic Acidosis in Liver Transplantation

GIK
Start date: February 2016
Phase: N/A
Study type: Interventional

Lactic acidosis is a common phenomenon occurring during orthotopic liver transplantation (OLT), especially during the anhepatic and early postreperfusion phases. However, little drugs effectively decrease the degree of lactic acidosis when it happens. The aim of this study is to explore whether glucose-Insulin-Potassium(GIK) infusion can relieve metabolic acidosis and improve perioperative outcome in patients undergoing OLT.

NCT ID: NCT03466528 Completed - Alcohol Withdrawal Clinical Trials

Alcohol: Thiamine and or Magnesium 1

AToM1
Start date: December 16, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

Patients who suffer Alcohol Use Disorder (AUD) have a 30-80% incidence of thiamine deficiency causing Wernicke's Encephalopathy (WE). Intravenous (IV) thiamine replacement is standard practice in the treatment of alcoholic patients presenting to the Accident & Emergency (A&E) department, however routine co-supplementation with magnesium (administered IV as magnesium sulphate ), which is required as a co-factor for thiamine in some metabolic processes, e. g. on the activity of the enzyme transketolase in red blood cells, is not routine practice in the treatment of these patients. Without correction of concomitant magnesium deficiency there may be impaired utilisation of thiamine resulting in a failure to treat WE. This study is designed to determine if administration of magnesium to AUD patients affects red cell transketolasae and serum lactate concentrations by itself, or only acts to increase the effect of thiamine on the activity of this enzyme.

NCT ID: NCT03432871 Recruiting - Clinical trials for Mitochondrial Diseases

Nicotinamide Riboside and Mitochondrial Biogenesis

Start date: December 8, 2017
Phase: N/A
Study type: Interventional

Mitochondria are important parts of the cell that are responsible for producing energy. The amount of energy they produce depends on how much energy the body needs to function and this energy production can be severely impaired in people with mitochondrial disease. Symptoms of mitochondrial disease vary widely but usually involve the brain, nerves and muscles, as these are tissues that need a lot of energy. Mitochondrial disorders affect 1 in 5000 of the UK population and there is currently no cure. Some scientists think that increasing the number of mitochondria in the body (mitochondrial biogenesis) might be an effective treatment for the symptoms of mitochondrial disease. Studies carried out in mice have shown that a type of B-vitamin called Nicotinamide Riboside (NR) is able to increase the number of mitochondria, leading to increased energy and a reduction in the symptoms of mitochondrial disease. The aim of this study is to investigate if the same B vitamin, Nicotinamide Riboside, can increase energy production and reduce symptoms in humans with mitochondrial disease. The study will consist of two parts: Part 1: Participants will be given a single oral dose of Nicotinamide Riboside and the levels of NR in their bloodstream will be measured at regular intervals. This will involve a single overnight stay and simple blood tests. Part 2: This requires 6 separate visits from each participant. Each participant will undergo a series of standard tests including a muscle biopsy and an MRI scan, then they will take a course of Nicotinamide Riboside (twice daily for 4 weeks). After 4 weeks of treatment, the participants will undergo the same tests again to see if there have been any changes in response to the treatment.

NCT ID: NCT03126890 Recruiting - Clinical trials for Peripheral Neuropathy

Investigation of the Correlation Between Plasma Concentration of Linezolid Antibiotic and Treatment Response and Adverse Reactions

Start date: December 2016
Phase: N/A
Study type: Observational

Linezolid is the second line agent in the treatment of MRSA and PRSP infections, and it is also the drug of choice for VRE infections. It can be an alternative option against multidrug resistant tuberculosis and non-tuberculosis mycobacterium. However, Patients who receive more than 2 weeks of treatment duration and who have renal dysfunction or severe cirrhosis may prone to experience anemia, thrombocytopenia, and leukopenia. Long-term use may also result in lactic acidosis, peripheral neuropathy and optic neuropathy due to mitochondrial toxicity. Thus, this study will analysis the medical charts in National Taiwan University Hospital (NTUH) from 2011 to 2016 to get the population demographics who use linezolid and analysis the occurrence rate of myelosuppression, neuropathy and lactic acidosis. Simultaneously, the investigators also use therapeutic drug monitoring (TDM) to prospectively evaluate the association of linezolid blood concentration and clinical efficacy and safety. The result of this study will provide physicians more information to prevent concentration-dependent adverse effects.

NCT ID: NCT03122678 Withdrawn - Septic Shock Clinical Trials

Thiamine Supplementation in Patients With Septic Shock

Start date: November 5, 2016
Phase: Phase 1
Study type: Interventional

To determine if intravenous thiamine would decrease the time to reversal of shock in patients with septic shock.

NCT ID: NCT02974257 Recruiting - Cardiac Arrest Clinical Trials

Thiamine vs. Placebo to Increase Oxygen Consumption After Cardiac Arrest

Start date: May 1, 2017
Phase: Phase 2
Study type: Interventional

This study is to evaluate whether thiamine can increase oxygen consumption and lower lactate in patients who initially survive an in-hospital cardiac arrest. Patients who are successfully resuscitated after an in-hospital cardiac arrest and who are on mechanical ventilation in the intensive care unit will be enrolled, and will get either thiamine or placebo. Their oxygen consumption and lactate will be measured at serial time points and compared between groups. The investigators' hypothesis is that thiamine will help restore the body's ability to metabolize oxygen normally (aerobic metabolism), leading to an increase in oxygen consumption and a decrease in lactate.